ClinicalTrials.gg
Not yet recruitingNCT07928414AT-GSHUpdated Nov 10, 2026

Reminiscence Therapy-Based Social Group Work for Older Adults in Long-Term Institutional Care

An interventional study of Reminiscence Therapy-Based Social Group Work in Risk of Mild Cognitive Impairment, Psychological Well-Being and Quality of Life, sponsored by Melike Türkmen. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Melike Türkmen · Not applicable, Interventional, and Supportive care

Updated Nov 10, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to find out whether a reminiscence therapy-based social group work intervention (AT-GSH) improves psychological well-being, quality of life, and cognitive status in older adults living in long-term institutional care who are at risk of mild cognitive impairment.

The main questions it aims to answer are:

  • Does AT-GSH improve psychological well-being shortly after the intervention?
  • Does AT-GSH improve psychological well-being at the 12-week follow-up?
  • Does AT-GSH improve quality of life and cognitive status shortly after the intervention and at the 12-week follow-up?

The study plans to include 44 adults aged 60 years or older who meet the study's screening criteria. Participants will be randomly assigned to an intervention group or a wait-list control group.

Participants in the intervention group will attend a preparation meeting followed by eight weekly, 60-minute face-to-face sessions in closed groups of 6 to 10 members. The sessions will involve recalling, sharing, and reflecting on memories from different periods of life.

Researchers will compare this group with participants in the wait-list control group, who will continue receiving the institution's usual health, care, and social activity services.

Participants in the intervention group will complete assessments before the intervention, within 1 to 7 days after the final intervention session, and 12 weeks (plus or minus one week) after the final session. Participants in the wait-list control group will complete assessments during the same calendar weeks. The main comparison will focus on psychological well-being shortly after the intervention, taking initial psychological well-being scores into account.

After the final follow-up assessment, the wait-list control group will be offered the same intervention on a voluntary basis.

Read the detailed description

AT-GSH is a structured social group work intervention grounded in an existential social work approach. The intervention combines structured reminiscence activities with group interaction and reflection on personal life experiences. It is guided by social work principles, including self-determination, respect for human dignity, voluntary participation, and mutual aid.

The intervention will be delivered by the researcher, who is a social worker, at a nursing home affiliated with Bursa Metropolitan Municipality, Turkiye. Each closed group will first attend a face-to-face preparation meeting lasting approximately 30 minutes. This meeting is separate from the eight thematic intervention sessions.

The intervention consists of eight weekly, 60-minute sessions. Sessions 1 to 7 address childhood, school life, youth, working life, family life, social ties, and later life, respectively. Session 8 focuses on reviewing life experiences and the planned termination of the group process.

Each session includes opening, reminiscence and reflection, and closing phases. Photographs, objects, music, and other memory-triggering materials may be used to facilitate recall and discussion. Participants may choose which experiences they wish to share.

The intervention protocol was structured in accordance with the Template for Intervention Description and Replication (TIDieR) checklist. Intervention fidelity will be documented using session implementation records and supported by face-to-face supervision after each session. Attendance at at least seven of the eight thematic sessions will be considered intervention completion.

Psychological well-being and quality of life will be assessed by an independent assessor who is unaware of group allocation. Cognitive status will be assessed by the certified researcher delivering the intervention, who is not blinded to group allocation.

The primary analysis will compare psychological well-being between the intervention and control groups shortly after the intervention while accounting for baseline scores. Additional analyses will examine psychological well-being at the 12-week follow-up and quality of life and cognitive status at both post-intervention and follow-up assessments.

02

Conditions studied

  • Risk of Mild Cognitive Impairment
  • Psychological Well-Being
  • Quality of Life

Keywords

  • Reminiscence Therapy
  • Social Group Work
  • Existential Social Work
  • Mild Cognitive Impairment Risk
  • Cognitive Status
  • Long-Term Institutional Care
  • Nursing Homes
  • Older Adults
03

In context

Psychological Well-Being

2,193 studies on the registry are indexed under Psychological Well-Being; 728 are open to participants now.

This study's planned enrollment of 44 is below the median of 110 across 1,796 interventional studies indexed under Psychological Well-Being.

Browse Psychological Well-Being studies →

Lead sponsor

This is the only study on the registry with Melike Türkmen as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 60 years or older and living in the participating nursing home
  • Cognitive complaint during the past year, reported by the participant or by responsible institutional staff (at least "sometimes" on either item)
  • Raw Turkish (MoCA-TR) score within the education-specific screening range: 16-17 for primary school graduates, 19-20 for middle school or high school graduates, and 20-22 for higher education graduates (Kaya et al., 2014); no education correction is applied
  • Largely preserved instrumental activities of daily living (Lawton Instrumental Activities of Daily Living Scale score of 6-8 out of 8)
  • At least primary school education
  • Able to communicate sufficiently to complete the assessments
  • Provides written and agrees to participate in group sessions

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of dementia, Alzheimer's disease, Parkinson's disease, or another progressive neurodegenerative disease, as reported by the participant or responsible institutional staff
  • Marked visual or hearing impairment that prevents assessment or group participation despite appropriate aids
  • Acute medical condition, suspected acute confusion or delirium, significant psychiatric problem, or neurological disorder that prevents safe group participation or valid assessment, as reported by the participant or responsible institutional staff or observed during assessment

The at-risk profile for mild cognitive impairment is a study-specific operational definition and does not constitute a clinical diagnosis of mild cognitive impairment.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    AT-GSH Intervention Group

    Participants will attend a face-to-face preparation meeting followed by eight weekly, 60-minute reminiscence therapy-based social group work (AT-GSH) sessions delivered by a social worker in closed groups of 6 to 10 members.

    Behavioral: Reminiscence Therapy-Based Social Group Work

  • No intervention
    Wait-List Control Group

    Participants will continue receiving the institution's usual health, care, and social activity services and will not receive AT-GSH until the final follow-up assessment. After the final follow-up assessment, they will be offered AT-GSH on a voluntary basis.

Interventions

  • BehavioralReminiscence Therapy-Based Social Group Work

    AT-GSH is a structured, face-to-face social group work intervention grounded in existential social work. It is delivered by a social worker in closed groups of 6 to 10 older adults. A preparation meeting of approximately 30 minutes precedes eight weekly, 60-minute sessions. The first seven sessions address childhood, school life, youth, working life, family life, social ties, and later life. The final session focuses on reviewing life experiences and ending the group process. Sessions include opening, reminiscence and reflection, and closing phases. Open-ended questions and memory-triggering materials facilitate voluntary sharing and reflection. Intervention fidelity is documented through session records and supervision.

    Also known as: AT-GSH

06

What researchers measure

Primary outcomes

  1. Psychological Well-Being Score at Post-Intervention

    Psychological well-being will be assessed using the Turkish version of the eight-item Flourishing Scale (Psychological Well-Being Scale; Diener et al., 2010; Telef, 2013), rated on a 7-point scale. Total scores range from 8 to 56, with higher scores indicating greater psychological well-being. Post-intervention scores will be compared between the intervention and wait-list control groups, adjusting for baseline scores. The scale is administered by an independent assessor blinded to group allocation.

    Time frame: Baseline (before randomization) and post-intervention (1 to 7 days after the final AT-GSH session; control group assessed during the same calendar week)

Secondary outcomes

  1. Psychological Well-Being Score at 12-Week Follow-Up

    Psychological well-being will be assessed using the Turkish version of the eight-item Flourishing Scale (Psychological Well-Being Scale). Total scores range from 8 to 56, with higher scores indicating greater psychological well-being. Follow-up scores will be compared between the intervention and wait-list control groups, adjusting for baseline scores. The scale is administered by an independent assessor blinded to group allocation.

    Time frame: Baseline (before randomization) and 12 weeks (plus or minus 1 week) after the final AT-GSH session; control group assessed during the same calendar week

  2. Quality of Life Score at Post-Intervention and 12-Week Follow-Up

    Quality of life will be assessed using the Turkish version of the 13-item Older People's Quality of Life Questionnaire-Brief (OPQOL-brief; Bowling et al., 2013; Caliskan et al., 2019), rated on a 5-point scale. Total scores range from 13 to 65, with higher scores indicating better quality of life. Scores will be compared between the intervention and wait-list control groups, adjusting for baseline scores. The scale is administered by an independent assessor blinded to group allocation.

    Time frame: Baseline (before randomization), post-intervention (1 to 7 days after the final AT-GSH session), and 12 weeks (plus or minus 1 week) after the final AT-GSH session; control group assessed during the same calendar weeks

  3. Cognitive Status Score at Post-Intervention and 12-Week Follow-Up

    Cognitive status will be assessed using the Turkish version of the Montreal Cognitive Assessment (MoCA-TR; Nasreddine et al., 2005; Selekler et al., 2010). Total scores range from 0 to 30, with higher scores indicating better cognitive performance. Scores will be compared between the intervention and wait-list control groups, adjusting for baseline scores. The test is administered by the certified researcher delivering the intervention, who is not blinded to group allocation.

    Time frame: Baseline (before randomization), post-intervention (1 to 7 days after the final AT-GSH session), and 12 weeks (plus or minus 1 week) after the final AT-GSH session; control group assessed during the same calendar weeks.

07

Study locations

1 site
  • Fethiye Dortcelik Nursing Home, Bursa Metropolitan Municipality
    Bursa, Bursa 16320, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. The informed consent obtained from participants does not cover sharing individual-level data with other researchers, and the small sample recruited from a single institution increases the risk of re-identification. Aggregated results will be reported in the doctoral thesis and related publications.

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07928414
Lead sponsor
Melike Türkmen
Responsible party
Melike Türkmen (Lecturer, Duzce University) — Sponsor-investigator
First posted
Nov 10, 2026
Start date
Nov 19, 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Melike Türkmen
Contact
meliketurkmen@duzce.edu.tr
+90 380 542 10 51 ext. 3411
Melike Türkmen
principal investigator · Duzce University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion